NEW YORK and TOKYO, June 6, 2011 – Jefferies announced today the addition of Naomi Kumagai, Makarim Salman and Masahiro Wakasugi as Senior Equity Research Analysts based in Tokyo. Ms. Kumagai will cover the Healthcare sector, Mr. Salman will cover the Financial Services and Insurance sectors, and Mr. Wakasugi will cover the Technology sector.
“The addition of these experienced analysts is another step in the continued expansion of Jefferies’ Asian Equities business,” commented Michael Alexander, CEO of Jefferies Asia. “Their strong industry expertise and proven track record will add immediate value to our global client base as we continue to build-out our equity platform in Asia.”
“We are pleased to welcome Naomi, Makarim and Masahiro to Jefferies. Their addition is part of Jefferies’ ongoing commitment to providing leading Asian equity research to our global client base,” added Nilesh Jasani, Head of Asia-Pacific Research.
Jefferies now has 15 equity research analysts covering over 75 companies in Asia. As part of the firm’s ongoing build-out in the region, Jefferies plans to continue to add equities professionals and expand research coverage accordingly.
Jefferies is establishing a full-service equity sales, trading, and research platform in Asia with a focus on Hong Kong, Japan, Singapore, India, Korea and Taiwan. The firm’s equities business now consists of more than 700 professionals globally, including over 200 outside the U.S. Jefferies offers sales and trading services in a full range of equity products, including cash equities, electronic trading, equity derivatives, exchange traded funds, convertibles, prime brokerage, securities finance and more than 215 equity research professionals globally covering over 1,100 companies.
Ms. Kumagai joins the firm from Macquarie Capital Securities, where she spent three years as a Senior Equity Research Analyst covering Healthcare and Pharmaceutical companies. Previously, she worked in business development at Banyu Pharmaceutical, a subsidiary of Merck, and prior to that worked as an Equity Research Analyst at Deutsche Trust Bank and Goldman Sachs, focusing on Healthcare companies. She also held project management roles at Eli Lilly and clinical development roles at Pfizer in Japan and the U.S. She received a BS and MS in Pharmaceutical Science at Toho University in Japan and an MBA from the Fuqua School of Business at Duke University.
Mr. Salman joins the firm from Macquarie Capital Securities, where he spent three years as a Senior Equity Research Analyst covering Insurance and Securities companies. Previously, he worked in the insurance industry for seven years as an Insurance Risk Officer at ING Life Japan and an Executive Advisor at KPMG, and prior to that, spent four years at HBoS Financial Services in a variety of roles. He received an MPhys from the University of Warwick in Mathematics and Physics and is a Fellow of the Institute of Actuaries.
Mr. Wakasugi joins the firm from AllianceBernstein, where he spent 10 years and was most recently a Senior Vice President and Equity Research Analyst. While at that firm, he was one of the portfolio managers for the Asian Technology Fund from 2005 to 2009, which won the Lipper Fund Award in the Information Technology sector in 2009. Previously, he spent four years at Mitsubishi UFJ Research and Consulting in Management Consulting. He received a BSe and MS in Financial Engineering from Waseda University.
Jefferies Group, Inc. (NYSE: JEF), a global securities and investment banking firm, has served companies and investors for nearly 50 years.
For further information, please contact: